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http://www.biomedcentral.com/1755-8794/5/23RESEARCH ARTICLE Open AccessBatch correction of microarray data substantially
improves the identification of genes
differentially expressed in Rheumatoid Arthritis
and Osteoarthritis
Peter Kupfer1, Reinhard Guthke1, Dirk Pohlers2,3, Rene Huber2,4, Dirk Koczan5 and Raimund W Kinne2*Abstract
Background: Batch effects due to sample preparation or array variation (type, charge, and/or platform) may
influence the results of microarray experiments and thus mask and/or confound true biological differences. Of the
published approaches for batch correction, the algorithm “Combating Batch Effects When Combining Batches of
Gene Expression Microarray Data” (ComBat) appears to be most suitable for small sample sizes and multiple
batches.
Methods: Synovial fibroblasts (SFB; purity> 98%) were obtained from rheumatoid arthritis (RA) and osteoarthritis
(OA) patients (n = 6 each) and stimulated with TNF-α or TGF-β1 for 0, 1, 2, 4, or 12 hours. Gene expression was
analyzed using Affymetrix Human Genome U133 Plus 2.0 chips, an alternative chip definition file, and normalization
by Robust Multi-Array Analysis (RMA). Data were batch-corrected for different acquiry dates using ComBat and the
efficacy of the correction was validated using hierarchical clustering.
Results: In contrast to the hierarchical clustering dendrogram before batch correction, in which RA and OA
patients clustered randomly, batch correction led to a clear separation of RA and OA. Strikingly, this applied not
only to the 0 hour time point (i.e., before stimulation with TNF-α/TGF-β1), but also to all time points following
stimulation except for the late 12 hour time point. Batch-corrected data then allowed the identification of
differentially expressed genes discriminating between RA and OA. Batch correction only marginally modified the
original data, as demonstrated by preservation of the main Gene Ontology (GO) categories of interest, and by
minimally changed mean expression levels (maximal change 4.087%) or variances for all genes of interest. Eight
genes from the GO category “extracellular matrix structural constituent” (5 different collagens, biglycan, and
tubulointerstitial nephritis antigen-like 1) were differentially expressed between RA and OA (RA>OA), both
constitutively at time point 0, and at all time points following stimulation with either TNF-α or TGF-β1.
Conclusion: Batch correction appears to be an extremely valuable tool to eliminate non-biological batch effects,
and allows the identification of genes discriminating between different joint diseases. RA-SFB show an upregulated
expression of extracellular matrix components, both constitutively following isolation from the synovial membrane
and upon stimulation with disease-relevant cytokines or growth factors, suggesting an “imprinted” alteration of
their phenotype.
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Gene expression microarray technology measures the ex-
pression of thousands of genes in one single array by using
multiple probes to assay each transcript. It is a widely-
used tool for identifying genes whose expression changes
in response to specific treatments. There are several con-
cerns with regard to the reliability of DNA microarray
technology in the study of diseases.
Microarray experiments are costly and time-consuming.
Many studies use multiple arrays, with experiments per-
formed at different times, on different array charges or
even with different microarray platforms. The resulting
gene expression data could thus be affected by non-
biological variables. These systematic differences between
the measurements are commonly referred to as “batch
effects”. There are several causes for batch effects, as out-
lined below:
 Ambient conditions during the sample preparation
and handling, such as room temperature and ozone
levels
 Storage and shipment conditions of the biological
samples and/or the arrays
 cRNA/cDNA synthesis
 Amplification, labeling, and hybridization protocol:
Use of reagents from different batches
 Sites/laboratories: Different laboratories have
different operating procedures
 Chip type/charge/platform: The array quality varies
from batch to batch
 Washing conditions: Temperature, ionic strength
 Scanner: Type, settings, and the calibration drift [1].
Although some of these batch effects can be minimized
or even prevented with appropriate precautions and ex-
perimental design, certain batch effects are unavoidable.
Some studies require large sample sizes and have to be
carried out over many months or sometimes years. In
clinical experiments, experiments are often driven by the
availability of the samples, which cannot be specifically
controlled for in the original study design. Combining
data from different batches without removing batch effects
can give rise to misleading results, since the bias intro-
duced by the non-biological nature of the batch effects
can be strong enough to mask and/or confound true bio-
logical differences. Thus, there is a need to identify and
remove these masking effects before further processing.
Microarray signal intensity normalization has been
widely used to adjust for experimental artifacts between
the samples. The effect of the normalization is to in-
crease the precision of multi-array measurements
through calibration of the signal intensity distributions.
There are several methods for normalization including
MAS5, Robust Multi-Array Analysis (RMA), and dChipfor Affymetrix chips, median scaling for GE-CodeLink
microarrays, and LOWLESS-based methods for cDNA
two-color microarrays. Common to all normalization
methods is that they are not specifically designed to re-
move batch effects reflected by systematic differences
between two or more groups of samples. Consequently,
batch effects may often remain after normalization.
However, of thousands of papers dealing with DNA
microarrays published in the last 5 years (>32,000), only
few address the potential existence of batch effects and/
or their correction. Of the 219 papers using microarray
data published from January 1 to July 1, 2010, not even
ten percent took this issue into account (NCBI GEO
database, studies with more than 30 samples) [2].
There are several published approaches to identify and
remove batch effects [1,3]. An Empirical Bayes method
called “Combating Batch Effects When Combining
Batches of Gene Expression Microarray Data” (ComBat)
estimates parameters for location and scale adjustment
of each batch for each gene independently [4-6]. In the
present study, this method was applied to a data subset
of 24 arrays (of a total of 120) in order to remove batch
effects due to different acquiry dates of the microarray
analyses. In contrast to the hierarchical clustering den-
drogram before batch correction, in which rheumatoid
arthritis (RA) and osteoarthritis (OA) patients clustered
randomly, batch correction led to a clear separation of
the RA and OA groups. Batch-corrected data then
allowed an unequivocal identification of differentially




Synovial membrane samples were obtained following tis-
sue excision upon joint replacement/synovectomy from
RA and OA patients (n = 6 each; all Caucasian; Tables 1
and 2) at the Clinic of Orthopedics, Waldkrankenhaus
“Rudolf Elle” (Eisenberg, Germany). Informed patient
consent was obtained and the study was approved by the
ethics committee of the University Hospital Jena. RA
patients were classified according to the American Col-
lege of Rheumatology (ACR) criteria valid in the sample
assessment period [7], OA patients according to the re-
spective criteria for osteoarthritis [8]. Negative purifica-
tion of primary synovial fibroblasts (SFB) from RA and
OA patients (purity: > 98%) was performed as previ-
ously described [9].
Cell stimulation and isolation of total RNA
At the end of the fourth passage, the SFB were washed
in serum-free DMEM and then stimulated by 10 ng/ml
TNF-α or TGF-β1 (PeproTech, Hamburg, Germany) in
serum-free DMEM for 0, 1, 2, 4, or 12 hours. At each

















EB87 F/65 12 + 50,00 106,7 5 NSAIDs
EB88 F/62 10 + 90,00 169,5 6 NSAIDs
EB213 F/69 15 + 94,00 99,1 4 NSAIDs,
Leflunomide,
Prednisolone
EB220 F/57 20 + 23,00 2,3 4 NSAIDs, MTX,
Prednisolone.
EB221 F/66 12 + 7,00 5,4 4 NSAIDs, MTX
EB227 F/49 25 + 12,00 2,4 5 NSAIDs, MTX,
Prednisolone.
Osteoarthritis
EB168 F/68 20 - 18,00 20,3 0 NSAIDs
EB173 F/81 2,5 - 38,00 32,0 2 NSAIDs,
Prednisolone.
EB190 M/56 5 - 6,00 0,5 1 NSAIDs
EB194 F/79 8 - 28,00 0,3 1 NSAIDs
EB202 M/65 5 - 7,00 3,0 0 NSAIDs
EB205 F/55 3 - 47,00 36,0 0 NSAIDs
ARA, American Rheumatism Association (now American College of
Rheumatology); CRP, C-reactive protein (normal range <5 mg/l); ESR,
erythrocyte sedimentation rate; F, female; M, male; MTX, methotrexate;
NSAIDs, non steroidal anti-inflammatory drugs; RF, rheumatoid factor;
-,negative; +, positive.
Table 2 Sample features (incl. acquiry date) and clinical
diagnosis of RA and OA patients
Batch Acquiry date Sample ID Treatment Diagnosis
1 2006-04-07 EB87.TGF.0 h TGF-β1 RA
EB87.TNF.0 h TNF-α
2 2006-11-30 EB190.TGF.0 h TGF-β1 OA
EB190.TNF.0 h TNF-α








5 2009-03-04 EB173.TGF.0 h TGF-β1 OA
EB173.TNF.0 h TNF-α
EB227.TGF.0 h TGF-β1 RA
EB227.TNF.0 h TNF-α
6 2009-03-14 EB194.TGF.0 h TGF-β1 OA
EB194.TNF.0 h TNF-α
EB213.TGF.0 h TGF-β1 RA
EB213.TNF.0 h TNF-α
7 2009-03-26 EB88.TGF.0 h TGF-β1
EB88.TNF.0 h TNF-α
EB168.TGF.0 h TGF-β1 OA
EB168.TNF.0 h TNF-α
All samples (total 120 arrays) were derived from 5 different time points of the
respective stimulation experiment. Batch = Integer label for the Batch
Correction; Acquiry date = date of hybridization of the microarray; Sample
ID = unique array identification; Stimulation = Stimulation of the samples;
Diagnosis =Disease of the patient.
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harvested after treatment with trypsin (0.25% in versene;
Invitrogen, Karlsruhe, Germany). After washing with
phosphate-buffered saline, they were lysed with RLT buf-
fer (Qiagen, Hilden, Germany) and frozen at −70°C.
Total RNA was isolated using the RNeasy Kit (Qiagen)
according to the supplier's recommendation.
Microarray analysis
Analysis of gene expression was performed using U133
Plus 2.0 RNA microarrays (Affymetrix, Santa Clara, CA,
USA; total of 120 microarrays). Labeling of RNA probes,
hybridization, and washing were carried out according
to the supplier's instructions. Microarrays were analyzed
by laser scanning (Hewlett-Packard Gene Scanner).
Original data from microarray analysis are accessible
through Gene Expression Omnibus series accession
number GSE13837 [10].
For annotating the genes, the alternative Chip Defin-
ition File (CDF) of Ferrari et al. was used to resolve the
problem of choosing reliable and non-contradictory pro-
besets for each transcript [11]. Several publications
demonstrated the advantage of such alternative CDFs
for the removal of cross-hybridization and other system-
based biases.The microarray data were preprocessed using RMA in
the default configuration for background adjustment and
normalization.
ComBat
For Batch correction of the patient data (Table 2), the
Empirical Bayes' (EB) method ComBat was used (non-
parametric prior method) [5]. EB methods are very
appealing in microarray analyses because of their ability
to robustly handle high-dimensional data derived from
small sample sizes. EB methods are primarily designed
to “borrow information” from a certain number of genes
and/or experimental conditions in order to obtain better
estimates or more stable inferences for the expression of
all genes. In several papers, EB methods were designed
to stabilize the expression values/ratios for genes with
extreme values or else the variance of genes or gene
groups by shrinking variances across all other genes,
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[6,12-19]. Johnson et al. extended the EB methods to the
problem of adjusting for batch effects in microarray
data, which are not addressed by the use of one or sev-
eral normalization procedures [5]. Johnson et al. pub-
lished a location and scale (L/S) adjustment method
for batch correction, which is available as R-package
ComBat at the developer's homepage [20]. In contrast to
other L/S methods, this method is the only procedure
currently known to robustly adjust batches with small
sample sizes.
As other L/S adjustments, ComBat assumes that the
batch effects can be modeled by standardizing means
and variances across batches. It uses a straightforward
L/S adjustment to independently center the mean and
standardize the variance for each gene in each batch.
This method incorporates systematic batch biases com-
mon across several genes to make adjustments on the
assumption that phenomena resulting in batch effects
often affect many genes in a similar way (i.e., increased
expression, higher variability, etc.). To determine the
data parameters which describe the particular L/S model
[5], ComBat estimates the L/S model parameters that
best represent the batch effects by “pooling information”
across some or all genes in each batch in order to
“shrink” the parameter estimates and thereby reduce the
influence of batch effects.
In the present study, a modified method of ComBat
was used to correct for batch effects among arrays gen-
erated at different dates. The algorithm was modified in
order to allow processing of RMA-normalized data in-
stead of dChip-normalized data. The Sample Informa-
tion File was created as described in the ComBat
manual. The creation date was tagged as “batch effect”
and the parameters time point (total of 5), disease group
(RA and OA), and stimulation (TNF-α and TGF-β1)
were marked as covariates for every array.
Limma
To identify differentially expressed genes, the software
Limma was used. Limma is an R-package for differential
expression analysis of data arising from microarray
experiments [21]. The package is designed to analyze
complex experiments involving simultaneous compari-
sons between many RNA targets. The basic concept is
to fit a linear model to the expression data for each gene.
The expression data from experiments are represented
as a data matrix with rows corresponding to probe sets
and columns to arrays. For the analysis with linear mod-
els, the approach requires two matrices. First, the design
matrix was created, which provides a representation of
the different RNA targets. Secondly, the contrast matrix
was generated, which allows to assign the coefficients
defined by the design matrix to contrasts of interests(in our case time point 0 hours, RA versus OA patients,
Table 2). Afterwards, the linear model was fitted using
the lmFit function, which fully models the systematic
part of the data. The actual analysis was analogous to
the classic t-test except that the eBayes-function was
used which employs the shrunken empirical Bayes esti-
mates [21]. Differentially expressed genes (DEG) were
obtained by using the toptable function and user-specific
thresholds (i.e., 2-fold changes in gene expression and a
q-value with a threshold of 0.05; [22]). The q-value (FDR
adjusted p-value) was calculated using the Benjamini
and Hochberg’s method [21].
GOstats
The Bioconductor package GOstats shows substantial
improvements for testing the association between Gene
Ontology (GO) terms and a given gene list [23]. Falcon
et al. implemented a conditional hypergeometric (hg)
test that uses the relationships among GO terms to ad-
dress the hierarchical structure of GO. To use this hg
test, the gene universe (in this case containing all genes
on the microarray) and a list of selected genes from that
universe was defined (DEG). After setting a cutoff for
the adjusted p-value of the hg test, GOstats returns a
GOHyperGResult with a summary of the test performed
and the number of significant GO terms. Furthermore,
the GOHyperGResult contains the expected gene count
and actual gene count for each GO term.
GPower
The Tool GPower 3.1.3 was used for post-hoc calcula-
tion of the power (1-ß error probability) of the t-test
with the error probability alpha = 0.05, where the sample
sizes of the two groups (RA, OA) were 12 each and the
respective mean values and SD of the two groups were
derived from Additional file 1: Table S1 [24,25].
Results
Clustering of RA and OA patients before and after batch
correction
Starting with RMA-normalized data of the 24 arrays for
time point 0, standard hierarchical clustering dendro-
grams (generated using the R function hclust with eu-
clidean distances) were employed to monitor the effect
of the batch correction by ComBat. These dendrograms
measure inter-cluster distances between the arrays. The
resulting distances can be interpreted as the dissimilarity
of the arrays
Before batch correction, the normalized data formed
clear clusters for the different batches (7 different
acquiry dates for groups of 2 – 4 individual Affymetrix
chips; Figure 1a). Except for 2 patients (extreme left and
extreme right), two main clusters were formed, separat-
ing the microarrays created in 2006 (red shades) from
Figure 1 Hierarchical clustering of uncorrected and batch-corrected data from time point 0 hours: a) The uncorrected data form
clusters reflecting the 7 different acquiry dates (red shades for arrays generated in 2006; blue shades for those generated in 2009; for
precise definition of the individual acquiry dates see Table 2). In contrast, RA and OA are not grouped. b) The ComBat-corrected data
(7 batches) form clusters reflecting the diseases (RA and OA) instead of the acquiry dates.
Figure 2 Venn Plot for genes differentially expressed between
RA and OA at time point 0 hours. BC results in a doubling of
differentially expressed genes (87! 181). A total of 57 genes
(65.51%) were represented in the intersection of the two gene lists
(DEG_over).
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pany providing the hybridization agents for the microar-
rays confirmed a change in the chemical components
used in the production process in the year 2007. As a
consequence of the batch effect, several unique clusters
were observed for the RA and OA patients (right and
left branches of the dendrogram), but other clusters
were mixed and contained members of both groups. In
addition, patient EB87 (extreme right cluster) showed
the highest dissimilarity with all arrays and was inter-
preted as an outlier, as also confirmed by Principal Com-
ponent Analysis (PCA; not shown).
Following batch correction for the 7 different acquiry
dates, the arrays instead formed two distinct clusters for
RA and OA in the hierarchical clustering dendrogram
(Figure 1b). The effects of the different creation dates
were completely removed and the outlier EB87 was inte-
grated, as also confirmed by PCA (not shown). This un-
equivocal clustering of RA and OA patients was only
achieved when correcting for 7 batches and not for 2yearly batches only (2006 and 2009; Additional file 2:
Figure S1).
Strikingly, distinct clustering for RA and OA following
batch correction for the 7 different acquiry dates was
not only observed at the 0 hour time point (i.e., before
Table 3 GO categories overrepresented in the gene set DEG_wBC (time point 0 hours) top-ranked with b) or without
BC a)
TermID Members (DEG/all) P-value Category
a)
GO:0005201 3/74 5.87e-03 extracellular matrix structural constituent
GO:0050840 2/26 6.62e-03 extracellular matrix binding
GO:0005100 2/28 7.65e-02 Rho GTPase activator activity
GO:0008307 2/40 1.52e-02 structural constituent of muscle
GO:0005178 2/57 2.96e-02 integrin binding
GO:0001871 3/154 3.61e-02 pattern binding
GO:0030246 3/156 3.70e-02 carbohydrate binding
b)
GO:0005201 8/74 7.60E-07 extracellular matrix structural constituent
GO:0048407 4/11 3.29E-06 platelet-derived growth factor binding
GO:0005540 3/19 9.04E-04 hyaluronic acid binding
GO:0015355 2/5 1.02E-03 secondary active monocarboxylate
transmembrane transporter activity
GO:0004035 2/6 1.52E-03 alkaline phosphatase activity
GO:0005178 4/57 2.74E-03 integrin binding
GO:0004000 2/9 3.58E-03 adenosine deaminase activity
GO:0050840 2/26 7.46E-03 extracellular matrix binding
GO:0008307 3/40 7.88E-03 structural constituent of muscle
GO:0046332 3/42 9.02E-03 SMAD binding
GO:0030674 3/44 1.02E-02 protein binding
GO:0016853 4/83 1.02E-02 isomerase activity
GO:0000287 10/441 1.53E-02 magnesium ion binding
GO:0005507 3/62 2.56E-02 copper ion binding
GO:0042802 7/289 3.17E-02 identical protein binding
GO:0005100 2/28 3.31E-02 Rho GTPase activator activity
GO:0005518 2/31 3.94E-02 collagen binding
GO:0016903 2/33 4.47E-02 oxidoreductase activity
GO categories overrepresented in both data sets are highlighted in bold. Please note that both the number of the category members and the p-values for
differential expression considerably improve by BC.
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points after stimulation except for the TGF-β1 late 12
hour time point (Additional file 3: Figure S2).
Comparison of differentially expressed genes before and
after batch correction
Limma was used to obtain differentially expressed genes
(DEG; ≥ 2-fold change; p-value of ≤ 0.05) for the key
question concerning a generic difference between RA
and OA patients. For the uncorrected data, 87 genes
were extracted (DEG_woBC). The batch-corrected data
contained 181 genes (DEG_wBC), with a total overlap of
65.51% (in total 57 genes; DEG_over) between the 2
gene sets. This was illustrated using a Venn plot
(Figure 2).For both data sets (DEG_woBC and DEG_wBC), a
gene enrichment analysis was done with GOstats
(p-value ≤ 0.05). In both data sets, the highest ranked
GO term was “extracellular matrix structural constitu-
ent” with a p-value of 5.87E-03 and 3/74 genes for the
uncorrected and a p-value of 7.60E-07 and 8/74 genes
for the corrected data set (Table 3). In addition, 5 of 7
GO categories identified before batch correction were
also overrepresented in the data set after batch correc-
tion, indicating that no major information was lost upon
batch correction (Table 3). Furthermore, the p-value of
the 3 genes from the top-ranked GO term contained in
both data sets largely improved following batch correc-
tion (by up to 20 orders of magnitude), underlining the
validity of the differential expression (Table 4).
Table 4 Genes of the top-ranked GO category (time point 0 hours) identified with b) or without BC a)
GC ID P-value SYMBOL ENTREZ ID Gene name
Without BC
GC01M103055_at 3.90E-05 COL11A1 1301 collagen, type XI, alpha 1
GC09P115957_at 3.73E-03 COL27A1 85301 collagen, type XXVII, alpha 1
GC0XP152413_at 3.59E-02 BGN 633 biglycan
With BC
GC01M103055_at 5.31E-25 COL11A1 1301 collagen, type XI, alpha 1
GC0XP152413_at 5.07E-12 BGN 633 biglycan
GC02P189547_at 1.39E-08 COL3A1 1281 collagen,type III, alpha 1
GC09P115957_at 2.98E-06 COL27A1 85301 collagen, type XXVII, alpha 1
GC01P031814_at 6.96E-05 TINAGL1 64129 tubulointerstitial nephritis antigen-like 1
GC07P093861_at 4.37E-04 COL1A2 1278 collagen, type I, alpha 2
GC02M189604_at 1.13E-03 COL5A2 1290 collagen, type V, alpha 2
GC17M045617_at 1.28E-02 COL1A1 1277 collagen, type I, alpha 1
Genes of the GO category (GO:0005201 extracellular matrix structural constituent) top-ranked with or without BC (see Table 3), including their p-value for
differential expression between RA and OA. Genes represented in both data sets are highlighted in bold. Please note that both the number of genes and the
p-value for differential expression considerably improve.
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or standardized variance induced by the batch correc-
tion, variance/mean plots were generated to illustrate
the “shrinkage” of the expression values. For this pur-
pose, the variances were standardized (range between 0
and 1) to prevent negative values. Analyzing the 181
genes from the DEG_wBC data set differentially
expressed between RA and OA, only marginal changes
of the means, but moderate to substantial reductions of
the variances were observed for all genes (Figure 3).
The same was true when the genes lost for analysis
following batch correction (DEG_lost; Figure 4 a,b), the
genes of interest from the GO term “extracellular matrix
structural constituent” (DEG_interest; Figure 4 c,d) or
all genes identified without batch correction (DEG_
woBC; Additional file 4: Figure S3) were displayed in the
variance/mean plot.
To further analyze the magnitude of changes in the
mean induced by the batch correction, the mean values
in both data sets were compared and the changes
expressed as percentages of the initial value; in both RA
and OA, very limited changes were observed (maximal
change 4.087%), either at the time point 0 hours (Table 5)
or at any time point following stimulation with TNF-α
or TGF-β1 (Additional file 1: Table S1). Despite the
limited changes of the means induced by BC, BC
resulted in a substantial improvement of the power for
the differentiation of RA and OA for all genes of interest
(Additional file 5: Table S2).
There was no indication for any type-1 error concern-
ing differential expression of the genes of interest, as
demonstrated by permuting the disease status (RA andOA) 20 times with subsequent BC; applying the thresh-
olds 2-FC and p< 0.05, none of the 8 genes of interest
were contained in the list of differentially expressed
genes for any of the permutations (Additional file 6:
Table S3). Also, a complete lack of clustering for RA and
OA was observed and, strikingly, the pairs of one patient
for the time point 0 were separated in some cases
(Additional file 7: Figure S4)
In addition to the differential expression between RA
and OA after BC for the 8 genes of interest from the
top-ranked GO term at time point 0 hours (Table 4b),
these genes also remained differentially expressed be-
tween RA and OA at all time points following stimula-
tion with either TNF-α or TGF-β1 (Figure 5, Additional
file 8: Table S4).
Discussion
In the present study, the ComBat method was highly
effective in removing batch effects due to different
acquiry dates of the microarrays; this was demonstrated
by i) unequivocal clustering of the RA and OA patients
in the batch-corrected data for almost all time points
investigated (shown by hierarchical clustering dendro-
grams and PCA); ii) integration of the outlier EB87,
resulting in reduced standardized variances for a number
of genes; iii) identification of a large number of genes
differentially expressed between RA and OA with highly
significant p-values (up to 5.31E-25); iv) identification of
numerous overrepresented GO terms (with an increased
number of members and strongly improved p-values).
The 7 different batches (aquiry dates) were clearly
grouped into the two main clusters representing microarray
Figure 3 Means and variances of 181 differentially expressed genes from the DEG_wBC set (time point 0 hours) in RA (a; n = 12; i.e. 6
patients with two replicates each) and OA (b; n = 12; i.e. 6 patients with two replicates each) with (red dots) or without BC (blue dots).
There are generally only marginal changes of the means, but moderate to substantial reductions of the variances, as indicated by an exclusively
horizontal shift.
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ters are a clear example of inevitable batch effects since the
supplier of the hybridization agents changed the chemical
components used in the production process in the year
2007 (personal communication; Affymetrix). The only pos-
sibility to avoid such batch effects would have been to col-
lect all the samples for simultaneous analysis, an approach
technically impossible for a total of 120 samples at the time
point of analysis (and possibly even today). In addition,unequivocal clustering of RA and OA patients was only
achieved when correcting for 7 batches and not only for 2
batches (2006 and 2009), indicating that both the technical
change of the supplier and a basic variance among the
acquiry dates contributed to the dissimilarity of the arrays.
This should be taken into consideration for future micro-
array analyses.
The batch correction had no major influence on the
underlying data, as demonstrated by i) almost unaffected
Figure 4 Means and variances of differentially expressed genes from the DEG_lost set (a,b; for definition see Figure 2) and the
DEG_interest set (c,d; for definition see Figure 2) in RA (a, c; n = 12) and OA (b, d; n = 12) patients with (red dots) or without BC (blue
dots). There are generally only marginal changes of the means, but moderate to substantial reductions of the variances.
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plots for a number of different gene sets; ii) marginally
changed, but mostly reduced standardized variances for
the same gene sets; iii) substantial overlap (> 65%) of
the genes differentially expressed between RA and OA
at time point 0 hours before and after batch correction;
iv) preservation of 5/7 of the top-ranked GO categories
after batch correction. These findings show that ComBatTable 5 Mean expression values of differentially expressed ge
RA
Symbol GCID Without BC With BC
COL1A1 GC17M045617_at 10.663 10.636
COL1A2 GC07P093861_at 13.894 13.895
COL3A1 GC02P189547_at 13.616 13.599
COL5A2 GC02M189604_at 11.664 11.659
COL11A1 GC01M103055_at 8.141 8.373
BGN GC0XP152413_at 10.201 10.131
TINAGL1 GC01P031814_at 6.580 6.742
COL27A1 GC09P115957_at 7.454 7.463
Mean expression values of differentially expressed genes of interest in RA and OA p
changes of the means in either RA or OA (up to 3.7%). For the full data of all stimuis highly suitable for batch correction of data derived
from small sample sizes and does not lead to inappropri-
ate modification of the underlying data as previously
published [2].
The genes up-regulated at time point 0 hours (identi-
fied following batch correction) reflected a key feature of
RA, i.e., SFB-driven fibrosis of the affected joints [26]. In
particular, the enhanced expression of collagens type Ines (time point 0 hours)
OA
Change (%) Without BC With BC Change (%)
-0.25 9.793 9.852 +0.60
+0.01 13.544 13.562 +0.13
-0.12 12.937 12.967 +0.23
-0.04 10.841 10.852 +0.10
+2.84 6.470 6.230 -3.70
-0.68 8.912 8.995 +0.93
+2.46 6.277 6.125 -2.42
+0.12 6.688 6.703 +0.23
atients with and without BC (time point 0 hours); there are only very limited
li and time points see Additional file 1: Table S1.
Figure 5 Time courses of genes of interest (DEG_interest; see Table 4b) in synovial fibroblasts from RA patients (blue and purple) or
OA (red and green) stimulated with TNF-α (red and blue) or TGF-β1 (green and purple). There were only marginal differences for the gene
expression values with or without BC (see also Additional file 1: Table S1). As expected, there was a clearly different regulation of the expression of
6 of 8 genes (BGN, COL1A1, COL27A1, COL5A2, COL1A2 and COL3A1; for definition of the abbreviations see Table 4) following stimulation of SFB
with either TNF-α or TGF-β1; this differential regulation was common for SFB from RA and OA patients (see Additional file 1: Table S1). However, 2
of 8 genes (COL11A1 and TINAGL) were regulated in a similar fashion by TNF-α and TGF-β1 in both RA and OA patients. Strikingly, significant
differences between RA and OA patients were observed for all genes of interest already at the time point 0 hours (see Additional file 8: Table S4a).
These differences were unaffected by stimulation with either TNF-α or TGF-β1.
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http://www.biomedcentral.com/1755-8794/5/23and III (COL1A1, COL1A2, COL3A1), as well as bigly-
can (BGN) by RA-SFB has been previously published
[27-29]. In the context of RA, collagens types V and XI
are less well known as mediators of fibrosis, but are tar-
gets of matrix metalloproteinase-mediated proteolytic
activity [30,31]. However, together with collagens type I,
II, and III, these collagens are defined as (fibrillar) inter-
stitial collagens [32] and represent major components of
the extracellular matrix [33], thus suggesting a potential
role in fibrosis also for these proteins. The fibrillar type
XXVII collagen (COL27A1) and lipocalin-7 (also known
as tubulointerstitial nephritis antigen-like 1; TINAGL1),
which were identified as up-regulated molecules in
RA-SFB in this study for the first time, are not intrinsic
extracellular matrix molecules, but both exhibit differen-
tiation potential. Type XXVII collagen, for example, is
predominantly expressed in cartilaginous tissues and
generally involved in skeletogenesis [34], whereas matri-
cellular lipocalin-7 appears to be a (positive) regulator of
angiogenesis [35], potentially influencing enhanced
angiogenesis in the synovial membrane [36]. Taken to-
gether, the enhanced formation of these matrix compo-
nents may contribute to joint fibrosis in an attempt to
counteract the progressive destruction of cartilage and
bone.
Strikingly, differential expression of the 8 genes of
interest from the top-ranked GO term “extracellular
matrix structural constituent” (DEG_interest) was not
only observed at the time point 0 hours, but also at all
time points following stimulation with either TNF-α or
TGF-β1. This suggests that RA-SFB show a constitu-
tively altered “rheumatic phenotype”, which is preserved
upon stimulation with TNF-α and TGF-β1 (“spacer ef-
fect”). Possible reasons for such an “imprinted” RA
phenotype may include both genomic changes, e.g.,
mutations or chromosome aberrations, or epigenetic
modifications, e.g. methylation or histone acetylation
status [37-39].
Conclusion
The present study clearly underscores the necessity of cor-
rection and removal of batch effects in the analysis of
microarray data. The application of batch correction
allowed the unequivocal identification of genes differentially
expressed between RA and OA and returned the top-
ranked GO category “extracellular matrix structural con-
stituent” (8/74 genes; p-value decreased by 4 orders of mag-
nitude). Batch correction strongly reduced the variance, but
only marginally influenced the mean expression levels, i.e.,
led to reliable results without falsification of the underlying
data.
RA-SFB show a constitutively altered “rheumatic pheno-
type”, which is preserved upon stimulation with TNF-α and
TGF-β1, suggesting an “imprinted” RA phenotype.Additional files
Additional file 1: Table S1. Mean expression values of differentially
expressed genes of interest in RA and OA patients with and without BC
for all time points.
Additional file 2: Figure S1. Hierarchical clustering of uncorrected and
batch-corrected data from time point 0: a) The uncorrected data form
clusters reflecting the 2 different years of acquiry (red shades for arrays
generated in 2006; blue shades for those generated in 2009). In contrast,
RA and OA are not grouped. b) The ComBat-corrected data (2 batches)
still fail to form clusters reflecting the diseases (RA and OA).
Additional file 3: Figure S2. Cluster plots for the time points 1, 2, 4,
and 12. a) Time point 1: TNF-α. b) Time point 1: TGF-β1. c) Time point 2:
TNF-α. d) Time point 2: TGF-β1. e) Time point 4: TNF-α. f) Time point 4:
TGF-β1. g) Time point 12: TNF-α. h) Time point 12: TGF-β1.
Additional file 4: Figure S3. Means and variances of differentially
expressed genes from the uncorrected data set (DEG_woBC) in RA (a)
and OA (b) patients with (red dots) or without BC (blue dots); there are
generally only marginal changes of the means, but moderate to
substantial reductions of the variances.
Additional file 5: Table S2. Comparison of the power values for the
differentiation of RA and OA before and after BC for the differentially
expressed genes [applied values: means ± standard deviations (SD)]
calculated using GPower [25].
Additional file 6: Table S3. Differentially expressed genes calculated
with LIMMA for 20 permutations.
Additional file 7: Figure S4. Cluster plots for time point 0 on the basis
of 20 permutations of the disease status (RA and OA).
Additional file 8: Table S4. Mann–Whitney U tests for the comparison
between RA and OA in a), or for the comparison between TNF-α and
TGF-β1 in b); +, significant difference; -, lack of significant difference; *,
significance test is not applicable (technical replicates).
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